



**STROKE**

**TBI**

**DEMENTIA**

## Increase quality of life with Cerebrolysin

Positive pharmacological effect in  
post-stroke-depression

Muresanu D.F. et al., **Cerebrolysin And Recovery after Stroke (CARS)**,  
Stroke 2016; 47:151-159

### CARS results - Cerebrolysin in patients after STROKE

- Improvement of motor functions
- Early recovery
- Regain full independence
- Increase quality of life

**Cerebrolysin**<sup>®</sup>

Reconnecting Neurons.  
Empowering for Life.

# Less development of post-stroke-depression

## High level of satisfied patients with their quality of life with Cerebrolysin

- Less dependence on caregivers early-on
- Early recovery motivates patients
- Post-stroke-depression is far less prevalent




Figure 1: Global status on day 90  
The effect sizes (Mann-Whitney MW) for the single and combined L(Wei-Lachin procedure) efficacy parameters reflect changes from baseline in the MITT-LOCF

## Cerebrolysin has positive influence on quality of life after stroke

- Major improvements was observed for **Depression** in Cerebrolysin group
- Earlier independence leads to **less post-stroke-depression** (GDS\*)
- Significant **better progress in patient's daily life** (SF36 PCS\*\*) reduces depression



full article

Published in  
**Stroke**

Stroke. January 2016;47:151-159  
Muresanu D.F. et al.

**Titel** Cerebrolysin And Recovery after Stroke (CARS) – A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial

**Patients** **104 Cerebrolysin group + 104 Placebo group = 208 patients in total**  
Cerebrolysin group = Cerebrolysin + Standard rehabilitation therapy  
Placebo group = Saline + Standard rehabilitation therapy

**Treatment** **30ml/day for 21 days** followed by 69 days treatment-free period  
Primary endpoint = ARAT score on day 90

\*GDS = Geriatric depression scale

\*\*SF36 PCS = Short Form 36 Items Health Survey – Physical Component

ABBREVIATED PRESCRIBING INFORMATION. Name of the medicinal product: Cerebrolysin - Solution for injection. Qualitative and quantitative composition: One ml contains 215.2 mg of Cerebrolysin concentrate in aqueous solution. List of excipients: Sodium hydroxide and water for injection. Therapeutic indications: For treatment of cerebrovascular disorders. Especially in the following indications: Senile dementia of Alzheimer's type. Vascular dementia. Stroke. Craniocerebral trauma (commotio and contusio). Contraindications: Hypersensitivity to one of the components of the drug, epilepsy, severe renal impairment. Marketing Authorisation Holder: EVER Neuro Pharma GmbH, A-4866 Unterach. Only available on prescription and in pharmacies. More information about pharmaceutical form, posology and method of administration, special warnings and precautions for use, interaction with other medicinal products and other forms of interaction, fertility, pregnancy and lactation, effects on ability to drive and use machines, undesirable effects, overdose, pharmacodynamics properties, pharmacokinetic properties, preclinical safety data, incompatibilities, shelf life, special precautions for storage, nature and contents of the container and special precautions for disposal is available in the summary of product characteristics.